Down Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Down Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays, and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes unusual for the child’s ethnic group, and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers, and excessive flexibility.
The Down Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Down Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 25 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Down Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Down Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Down Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AC Immune SAAelis Farma SAS
Alzheon Inc
Avanti Biosciences Inc
Balance Therapeutics Inc
Connecta Therapeutics SL
Eisai Co Ltd
Elixirgen Therapeutics Inc
F. Hoffmann-La Roche Ltd
Guangzhou Institute of Biomedicine and Health
IAMA Therapeutics Srl
Iluminos Therapeutics LLC
Italian Institute of Technology
KinoPharma Inc
Les Laboratoires Servier SAS
ManRos Therapeutics
NeuroCircuit Therapeutics Inc
NeuroNascent Inc
NeuroTau Inc
Partner Therapeutics Inc
Perha Pharmaceuticals SAS
Prothena Corp Plc
SanBio Co Ltd
University of California Davis
University of California San Diego
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Down Syndrome reports